Ameliorating Contrast Induced Nephropathy After Coronary Angiography

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT06139952

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06139952
Other papers using this trial's data
  • Preventing Contrast-Induced Acute Kidney Injury in Egyptian Patients Undergoing Coronary Angiography: A Randomized Controlled Trial Clinical drug investigation, 2026-04 DOI, PubMed 41701447, PMC12999647 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06139952. Randomized; single masking; primary purpose prevention. Start 2023-12-01 (actual); primary completion 2024-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ameliorating Contrast Induced Nephropathy After Coronary Angiography
Condition
Nephropathy; Toxic, Drugs
Intervention (Drug)
Atorvastatin 80mg
Intervention (Drug)
N-acetyl cysteine
Intervention (Other)
Normal Saline
Lead sponsor
Ain Shams University (class: other)

Record details

Record id
cardio:ct-nct06139952
Content hash
a7f7ffc4abc042623388e192b03f9c10ed3f9b0caedbf1b1254e4bbe7543f0b0